Viteyes AREDS 2 and Lower Zinc

ViteyesUncategorized

Viteyes® AREDS 2 formula is based on the findings from the National Eye Institute’s AREDS 2 study.* Viteyes AREDS 2 formula contains lower zinc which we feel is the safest and best option for our patients.

Why does Viteyes AREDS 2 formula contain lower zinc (25 mg)?

No statistically significant difference in effectiveness with less zinc
o The AREDS 2 study showed there was no statistically significant effect on progression to advanced AMD between 25 mg of zinc and 80 mg of zinc recommended in the original AREDS study.
o The AREDS 2 study also tested the AREDS formulation with a lower dose of zinc (25 mg) because data suggested that this may be the maximal level absorbed.

Less potential for stomach irritation
o The original AREDS report (a ten year study) showed gastrointestinal issues were more common in participants who took zinc (80 mg) than a placebo.**

– Anemia
o There is less concern for copper deficiency anemia.

In response to the AREDS 2 study, Viteyes® AREDS 2 formulas omit beta-carotene and add lutein and zeaxanthin, which is shown to have better results to slow the progression to advanced AMD than the original AREDS formula released in 2001. Viteyes® AREDS 2 Formula contains a daily dosing of vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, copper 1.2 mg and zinc 25 mg.

In response to the AREDS 2 study, Viteyes® AREDS 2 formula omits beta-carotene and adds lutein and zeaxanthin, which is shown to have better results to slow the progression to advanced AMD than the original AREDS formula released in 2001. Viteyes® AREDS 2 Formula contains a daily dosing of vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, copper 1.2 mg and zinc 25 mg.
Order Viteyes® AREDS 2 formula now or learn more by clicking here.

 

 

*The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA, 2013—Vol 309, No. 19, Pages 1-11.
**Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss. AREDS Report No. 8. Archives of Ophthalmology, 2001—Vol 119.